Zydus Lifesciences Ltd. has successfully completed its cash tender offer for the acquisition of all outstanding shares of common stock of U.S.-based Assertio Holdings, Inc., marking a significant milestone in the company's strategy to expand its footprint in the United States pharmaceutical market.

The tender offer was executed through Zara Merger Sub Inc., a wholly owned subsidiary of Zydus Lifesciences, at a purchase price of US$23.50 per share in cash, subject to applicable withholding taxes.

At the expiration of the tender offer on June 15, 2026, a total of 4,286,488 shares of Assertio common stock had been validly tendered and not withdrawn, representing approximately 66.32% of Assertio's total issued and outstanding shares. Zydus has accepted all validly tendered shares for payment and expects to complete the payment process promptly.

The company plans to finalize the transaction through a merger of Zara Merger Sub Inc. with and into Assertio. Upon completion of the merger, all remaining Assertio shares that were not tendered will be converted into the right to receive the same cash consideration of US$23.50 per share, subject to applicable tax deductions.

Following the merger, Assertio will operate as a wholly owned subsidiary of Zydus Lifesciences. The company's common stock will be delisted from the Nasdaq Global Market and will cease trading as a publicly listed entity.

The acquisition is expected to enhance Zydus' commercial capabilities and specialty pharmaceutical portfolio in the U.S., further strengthening its presence in one of the world's largest pharmaceutical markets.

The transaction aligns with the company's long-term growth strategy of expanding its global operations through targeted acquisitions and portfolio diversification.